Xiaohan Wu

Shenyang, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Fusobacterium nucleatum exacerbates colitis via STAT3 activation induced by Acetyl-CoA accumulation.

Fusobacterium nucleatum exacerbates colitis via STAT3 activation induced by Acetyl-CoA accumulation.

Journal: Gut microbes
Published: April 11, 2025

Metformin attenuates colitis via blocking STAT3 acetylation by reducing acetyl-CoA production.

Metformin attenuates colitis via blocking STAT3 acetylation by reducing acetyl-CoA production.

Journal: Journal of advanced research
Published: October 15, 2024

Dietary long-chain fatty acids promote colitis by regulating palmitoylation of STAT3 through CD36-mediated endocytosis.

Dietary long-chain fatty acids promote colitis by regulating palmitoylation of STAT3 through CD36-mediated endocytosis.

Journal: Cell death & disease
Published: September 12, 2023

2'-Fucosyllactose restores the intestinal mucosal barrier in ulcerative colitis by inhibiting STAT3 palmitoylation and phosphorylation.

2'-Fucosyllactose restores the intestinal mucosal barrier in ulcerative colitis by inhibiting STAT3 palmitoylation and phosphorylation.

Journal: Clinical nutrition (Edinburgh, Scotland)
Published: September 07, 2023

Exosomal-miR-129-2-3p derived from Fusobacterium nucleatum-infected intestinal epithelial cells promotes experimental colitis through regulating TIMELESS-mediated cellular senescence pathway.

Exosomal-miR-129-2-3p derived from Fusobacterium nucleatum-infected intestinal epithelial cells promotes experimental colitis through regulating TIMELESS-mediated cellular senescence pathway.

Journal: Gut microbes
Published: August 08, 2023

2'-Hydroxycinnamaldehyde Alleviates Intestinal Inflammation by Attenuating Intestinal Mucosal Barrier Damage Via Directly Inhibiting STAT3.

2'-Hydroxycinnamaldehyde Alleviates Intestinal Inflammation by Attenuating Intestinal Mucosal Barrier Damage Via Directly Inhibiting STAT3.

Journal: Inflammatory bowel diseases
Published: July 14, 2023

Dihydrokaempferol attenuates CCl4-induced hepatic fibrosis by inhibiting PARP-1 to affect multiple downstream pathways and cytokines.

Dihydrokaempferol attenuates CCl4-induced hepatic fibrosis by inhibiting PARP-1 to affect multiple downstream pathways and cytokines.

Journal: Toxicology and applied pharmacology
Published: October 27, 2022

Performance improvement of Hf0.45Zr0.55Oxferroelectric field effect transistor memory with ultrathin Al-O bonds-modified InOxchannels.

Performance improvement of Hf0.45Zr0.55Oxferroelectric field effect transistor memory with ultrathin Al-O bonds-modified InOxchannels.

Journal: Nanotechnology
Published: October 25, 2022

Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis.

Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis.

Journal: Autoimmunity
Published: July 25, 2022

Fusobacterium nucleatum Extracellular Vesicles Promote Experimental Colitis by Modulating Autophagy via the miR-574-5p/CARD3 Axis.

Fusobacterium nucleatum Extracellular Vesicles Promote Experimental Colitis by Modulating Autophagy via the miR-574-5p/CARD3 Axis.

Journal: Inflammatory bowel diseases
Published: June 01, 2022

P2RY13 Exacerbates Intestinal Inflammation by Damaging the Intestinal Mucosal Barrier via Activating IL-6/STAT3 Pathway.

P2RY13 Exacerbates Intestinal Inflammation by Damaging the Intestinal Mucosal Barrier via Activating IL-6/STAT3 Pathway.

Journal: International journal of biological sciences
Published: April 22, 2022
Showing 1-11 of 11

Last Updated: 09/26/2026